Polynitroxylated pegylated hemoglobin (PNPH): A nanomedicine for critical care and transfusion

Li Ma; Frances M. Thompson; Dong Wang; Carleton J.C. Hsia

doi:10.1007/978-3-642-40717-8_16

Polynitroxylated pegylated hemoglobin (PNPH): A nanomedicine for critical care and transfusion

Li Ma, Frances M. Thompson, Dong Wang, Carleton J.C. Hsia

Biochemistry, Chemistry & Physics

Research output: Contribution to book or proceeding › Chapter › peer-review

3 Scopus citations

Abstract

Polynitroxylated pegylated hemoglobin (PNPH, VitalHeme™, SynZyme Technologies LLC, Irvine, CA) is a pegylated hemoglobin covalently labeled with catalytic nitroxides, aka caged nitric oxide (cNO). PNPH serves as a hyperoncotic biopolymer coated and redox transformed hemoglobin acting in the plasma phase as a neurovascular protective multifunctional nanomedicine. This drug is for the correction or prevention of inadequate regional and/or global blood flow without oxidative stress under normal or hypovolemic states in critical care and transfusion medicine. Specific clinical indications for which PNPH has shown efficacy are traumatic brain injury complicated by hemorrhagic shock, stroke, and sickle cell disease. PNPH may also be an ideal alternative to aged red blood cells and a bridge to transfusion.

Original language	English
Title of host publication	Hemoglobin-Based Oxygen Carriers as Red Cell Substitutes and Oxygen Therapeutics
Publisher	Springer-Verlag Berlin Heidelberg
Pages	299-313
Number of pages	15
Volume	9783642407178
ISBN (Electronic)	9783642407178
ISBN (Print)	3642407161, 9783642407161
DOIs	https://doi.org/10.1007/978-3-642-40717-8_16
State	Published - Oct 1 2013

Scopus Subject Areas

General Engineering
General Materials Science
General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1007/978-3-642-40717-8_16

Cite this

@inbook{533e26348b3746f88d48b4b9cdfbeed3,

title = "Polynitroxylated pegylated hemoglobin (PNPH): A nanomedicine for critical care and transfusion",

abstract = "Polynitroxylated pegylated hemoglobin (PNPH, VitalHeme{\texttrademark}, SynZyme Technologies LLC, Irvine, CA) is a pegylated hemoglobin covalently labeled with catalytic nitroxides, aka caged nitric oxide (cNO). PNPH serves as a hyperoncotic biopolymer coated and redox transformed hemoglobin acting in the plasma phase as a neurovascular protective multifunctional nanomedicine. This drug is for the correction or prevention of inadequate regional and/or global blood flow without oxidative stress under normal or hypovolemic states in critical care and transfusion medicine. Specific clinical indications for which PNPH has shown efficacy are traumatic brain injury complicated by hemorrhagic shock, stroke, and sickle cell disease. PNPH may also be an ideal alternative to aged red blood cells and a bridge to transfusion.",

author = "Li Ma and Thompson, {Frances M.} and Dong Wang and Hsia, {Carleton J.C.}",

year = "2013",

month = oct,

day = "1",

doi = "10.1007/978-3-642-40717-8_16",

language = "English",

isbn = "3642407161",

volume = "9783642407178",

pages = "299--313",

booktitle = "Hemoglobin-Based Oxygen Carriers as Red Cell Substitutes and Oxygen Therapeutics",

publisher = "Springer-Verlag Berlin Heidelberg",

}

Polynitroxylated pegylated hemoglobin (PNPH): A nanomedicine for critical care and transfusion. / Ma, Li; Thompson, Frances M.; Wang, Dong et al.
Hemoglobin-Based Oxygen Carriers as Red Cell Substitutes and Oxygen Therapeutics. Vol. 9783642407178 Springer-Verlag Berlin Heidelberg, 2013. p. 299-313.

Research output: Contribution to book or proceeding › Chapter › peer-review

TY - CHAP

T1 - Polynitroxylated pegylated hemoglobin (PNPH)

T2 - A nanomedicine for critical care and transfusion

AU - Ma, Li

AU - Thompson, Frances M.

AU - Wang, Dong

AU - Hsia, Carleton J.C.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Polynitroxylated pegylated hemoglobin (PNPH, VitalHeme™, SynZyme Technologies LLC, Irvine, CA) is a pegylated hemoglobin covalently labeled with catalytic nitroxides, aka caged nitric oxide (cNO). PNPH serves as a hyperoncotic biopolymer coated and redox transformed hemoglobin acting in the plasma phase as a neurovascular protective multifunctional nanomedicine. This drug is for the correction or prevention of inadequate regional and/or global blood flow without oxidative stress under normal or hypovolemic states in critical care and transfusion medicine. Specific clinical indications for which PNPH has shown efficacy are traumatic brain injury complicated by hemorrhagic shock, stroke, and sickle cell disease. PNPH may also be an ideal alternative to aged red blood cells and a bridge to transfusion.

AB - Polynitroxylated pegylated hemoglobin (PNPH, VitalHeme™, SynZyme Technologies LLC, Irvine, CA) is a pegylated hemoglobin covalently labeled with catalytic nitroxides, aka caged nitric oxide (cNO). PNPH serves as a hyperoncotic biopolymer coated and redox transformed hemoglobin acting in the plasma phase as a neurovascular protective multifunctional nanomedicine. This drug is for the correction or prevention of inadequate regional and/or global blood flow without oxidative stress under normal or hypovolemic states in critical care and transfusion medicine. Specific clinical indications for which PNPH has shown efficacy are traumatic brain injury complicated by hemorrhagic shock, stroke, and sickle cell disease. PNPH may also be an ideal alternative to aged red blood cells and a bridge to transfusion.

UR - http://www.scopus.com/inward/record.url?scp=84895746220&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-40717-8_16

DO - 10.1007/978-3-642-40717-8_16

M3 - Chapter

AN - SCOPUS:84895746220

SN - 3642407161

SN - 9783642407161

VL - 9783642407178

SP - 299

EP - 313

BT - Hemoglobin-Based Oxygen Carriers as Red Cell Substitutes and Oxygen Therapeutics

PB - Springer-Verlag Berlin Heidelberg

ER -

Polynitroxylated pegylated hemoglobin (PNPH): A nanomedicine for critical care and transfusion

Abstract

Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this